Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.56 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.56 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.56 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.56 |
| ▸ | CDK1 | P06493 | 1/20 | 0.51 |
| ▸ | PYGM | P11217 | 3/20 | 0.47 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.46 |
| ▸ | CDA | P32320 | 2/20 | 0.44 |
| ▸ | TK2 | O00142 | 2/20 | 0.44 |
| ▸ | PNP | P00491 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL42101 | 1.00 | SLC28A1 (0.56) | SLC28A1SLC28A2SLC29A1SLC28A3CDK1 | |
| SCHEMBL13423825 | 1.00 | SLC28A1 (0.56) | SLC28A1SLC28A2SLC29A1SLC28A3CDK1 | |
| SCHEMBL7152755 | 1.00 | SLC28A1 (0.56) | SLC28A1SLC28A2SLC29A1SLC28A3CDK1 | |
| SCHEMBL12143115 | 1.00 | SLC28A1 (0.56) | SLC28A1SLC28A2SLC29A1SLC28A3CDK1 | |
| SCHEMBL12143539 | 1.00 | SLC28A1 (0.56) | SLC28A1SLC28A2SLC29A1SLC28A3CDK1 | |
| SCHEMBL14146449 | 1.00 | SLC28A1 (0.56) | SLC28A1SLC28A2SLC29A1SLC28A3CDK1 | |
| SCHEMBL14546409 | 1.00 | SLC28A1 (0.56) | SLC28A1SLC28A2SLC29A1SLC28A3CDK1 | |
| Phosphoric Acid SCHEMBL15522443 | 0.95 | SLC28A1 (0.52) | SLC28A1SLC28A2SLC29A1SLC28A3CDK1 | |
| SCHEMBL7146490 | 0.94 | SLC28A1 (0.51) | SLC28A1SLC28A2SLC29A1SLC28A3CDK1 | |
| SCHEMBL29623888 | 0.87 | CDK1 (0.61) | SLC28A1SLC28A2SLC29A1SLC28A3CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3422 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078356-A1 | COMPOSITIONS AND METHODS FOR TREATING ORNITHINE TRANSCARBAMYLASE DEFICIENCY | ARCTURUS THERAPEUTICS INC (US) | 2026-03-19 | — | — | US | claimed |
| US-12398379-B2 | Compositions and methods for treating ornithine transcarbamylase deficiency | ARCTURUS THERAPEUTICS, INC. (US) | 2025-08-26 | — | — | US | claimed |
| US-20240002815-A1 | COMPOSITIONS AND METHODS FOR TREATING ORNITHINE TRANSCARBAMYLASE DEFICIENCY | ARCTURUS THERAPEUTICS, INC. | 2024-01-04 | — | — | US | claimed |
| US-11685906-B2 | Compositions and methods for treating ornithine transcarbamylase deficiency | ARCTURUS THERAPEUTICS, INC. (US) | 2023-06-27 | — | — | US | claimed |
| US-20220282252-A1 | Compositions and Methods for MYC Messenger RNA Inhibitors | UNIV JEFFERSON (US) | 2022-09-08 | — | — | US | claimed |
| US-11000547-B2 | Compositions related to rna in circularized form | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-05-11 | — | — | US | claimed |
| US-20200181584-A1 | COMPOSITIONS AND METHODS FOR TREATING ORNITHINE TRANSCARBAMYLASE DEFICIENCY | ARCTURUS THERAPEUTICS, INC. | 2020-06-11 | — | — | US | claimed |
| US-20180169146-A1 | COMPOSITIONS AND METHODS FOR TRANSIENT GENE THERAPY WITH ENHANCED STABILITY | DANA-FARBER CANCER INSTITUTE, INC. | 2018-06-21 | — | — | US | claimed |
| EP-3303377-A1 | COMPOSITIONS AND METHODS FOR TRANSIENT GENE THERAPY WITH ENHANCED STABILITY | Dana-Farber Cancer Institute, Inc. (US) | 2018-04-11 | — | — | EP | claimed |
| WO-2016197121-A1 | COMPOSITIONS AND METHODS FOR TRANSIENT GENE THERAPY WITH ENHANCED STABILITY | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-12-08 | — | — | WO | claimed |
| WO-1998050530-A2 | ENZYMATIC NUCLEIC ACIDS: SYNTHESIS, SELECTION AND USE | RIBOZYME PHARMACEUTICALS, INC. (US) | 1998-11-12 | — | — | WO | claimed |
| WO-1998033893-A2 | RIBOZYMES CLEAVING EPIDERMAL GROWTH FACTOR RECEPTORS | RIBOZYME PHARMACEUTICALS, INC. (US) | 1998-08-06 | — | — | WO | claimed |
| WO-1998032846-A2 | ENZYMATIC NUCLEIC ACID TREATMENT OF DISEASES OR CONDITIONS RELATED TO LEVELS OF C-FOS | RIBOZYME PHARMACEUTICALS, INC. (US) | 1998-07-30 | — | — | WO | claimed |
| EP-0799313-A2 | METHOD AND REAGENT FOR TREATMENT OF ARTHRITIC CONDITIONS, INDUCTION OF GRAFT TOLERANCE AND REVERSAL OF IMMUNE RESPONSES | RIBOZYME PHARMACEUTICALS, INC. (US) | 1997-10-08 | — | — | EP | claimed |
| WO-1997026270-A2 | SYNTHESIS OF METHOXY NUCLEOSIDES AND ENZYMATIC NUCLEIC ACID MOLECULES | RIBOZYME PHARMACEUTICALS, INC. (US) | 1997-07-24 | — | — | WO | claimed |
| US-5646042-A | RESTENOSIS, CANCER | RIBOZYME PHARMACEUTICALS, INC. (US) | 1997-07-08 | — | — | US | claimed |
| EP-0763106-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF RESTENOSIS AND CANCER USING RIBOZYMES | RIBOZYME PHARMACEUTICALS, INC. (US) | 1997-03-19 | — | — | EP | claimed |
| US-5612215-A | INHIBITION OF OSTEOARTHRITIS | RIBOZYME PHARMACEUTICALS, INC. (US) | 1997-03-18 | — | — | US | claimed |
| WO-1996018736-A2 | METHOD AND REAGENT FOR TREATMENT OF ARTHRITIC CONDITIONS, INDUCTION OF GRAFT TOLERANCE AND REVERSAL OF IMMUNE RESPONSES | RIBOZYME PHARMACEUTICALS, INC. (US) | 1996-06-20 | — | — | WO | claimed |
| WO-1995031541-A2 | METHODS AND COMPOSITIONS FOR TREATMENT OF RESTENOSIS AND CANCER USING RIBOZYMES | RIBOZYME PHARMACEUTICALS, INC. (US) | 1995-11-23 | — | — | WO | claimed |